Join us for a lunch time session on "Accelerating research translation of mRNA-based innovation"
12:45 p.m. Wednesday 27 May 2026
Meeting Room 519, Palais des congrès, Montreal, Canada
This session is only open to the attendees of the RNA Society 31st Annual Meeting.
Complimentary lunch will be provided.
Registration to attend this BioNTech session is required for catering purposes. Attendance is capped at 200 due to room capacity.
About the session
The rapid deployment of mRNA‑based COVID‑19 vaccines has accelerated the emergence of mRNA as a versatile platform with the potential to transform vaccines, oncology, infectious diseases, and beyond. mRNA medicines can be engineered to encode antigens, antibodies, cytokines, and therapeutic proteins, potentially enabling new classes of innovative vaccines and immunotherapies.
This seminar will explore how advances in mRNA design, delivery, and manufacturing are translating RNA research into clinical‑stage medicines. We will cover some of BioNTech’s innovative mRNA design principles and applications in the context of mRNA optimisation. Drawing on BioNTech’s experience in developing mRNA as a scalable platform technology, the session will highlight key scientific and strategic considerations along the pathway from discovery to first‑in‑human studies.
In Australia, BioNTech has established an Innovation Centre and R&D laboratory and is building clinical GMP mRNA manufacturing capacity, enabled by modular BioNTainer infrastructure for drug substance and formulated products, including fill-and‑finish capabilities. BioNTech supports researchers and companies through scientific guidance, translational support, and access to research‑ and clinical‑scale manufacturing.
Attendees will gain a practical, end-to-end view of key decision points and capabilities that may help to accelerate the translation of mRNA programs into clinical trials and beyond.
Speakers
BioNTech is pleased to welcome the following speakers who will share practical insights into the key steps and capabilities required to accelerate the development of the mRNA-based innovation and approaches:
Meet the BioNTech Speakers at the Poster Session on Wednesday 27 May 2026
If you have questions about the progressing mRNA-based therapeutics or vaccines, please visit us at the BioNTech Poster.
